These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 38185043)

  • 21. Chrysin-Loaded Chitosan Nanoparticle-Mediated Neuroprotection in Aβ
    Saleem S; Banerjee R; Rajesh Kannan R
    ACS Chem Neurosci; 2022 Jul; 13(13):2017-2034. PubMed ID: 35696319
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enhancing autophagy in Alzheimer's disease through drug repositioning.
    Eshraghi M; Ahmadi M; Afshar S; Lorzadeh S; Adlimoghaddam A; Rezvani Jalal N; West R; Dastghaib S; Igder S; Torshizi SRN; Mahmoodzadeh A; Mokarram P; Madrakian T; Albensi BC; Łos MJ; Ghavami S; Pecic S
    Pharmacol Ther; 2022 Sep; 237():108171. PubMed ID: 35304223
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Repurposing drugs against Alzheimer's disease: can the anti-multiple sclerosis drug fingolimod (FTY720) effectively tackle inflammation processes in AD?
    Leßmann V; Kartalou GI; Endres T; Pawlitzki M; Gottmann K
    J Neural Transm (Vienna); 2023 Aug; 130(8):1003-1012. PubMed ID: 37014414
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Unlocking the concealed targets using system biology mapping for Alzheimer's disease.
    Joshi P; Kawade V; Dhulap S; Goel M
    Pharmacol Rep; 2019 Dec; 71(6):1104-1107. PubMed ID: 31634797
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Repurposing Antihypertensive Drugs for the Management of Alzheimer's Disease.
    Law CSW; Yeong KY
    Curr Med Chem; 2021; 28(9):1716-1730. PubMed ID: 32164502
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of embryonic cyclosporine exposures on brain development and behavior.
    Clift DE; Thorn RJ; Passarelli EA; Kapoor M; LoPiccolo MK; Richendrfer HA; Colwill RM; Creton R
    Behav Brain Res; 2015 Apr; 282():117-24. PubMed ID: 25591474
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tackling Alzheimer's Disease with Existing Drugs: A Promising Strategy for Bypassing Obstacles.
    Rampa A; Gobbi S; Belluti F; Bisi A
    Curr Med Chem; 2021; 28(12):2305-2327. PubMed ID: 32867634
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Repurposed agents in the Alzheimer's disease drug development pipeline.
    Bauzon J; Lee G; Cummings J
    Alzheimers Res Ther; 2020 Aug; 12(1):98. PubMed ID: 32807237
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative behavioral toxicology with two common larval fish models: Exploring relationships among modes of action and locomotor responses.
    Steele WB; Kristofco LA; Corrales J; Saari GN; Haddad SP; Gallagher EP; Kavanagh TJ; Kostal J; Zimmerman JB; Voutchkova-Kostal A; Anastas P; Brooks BW
    Sci Total Environ; 2018 Nov; 640-641():1587-1600. PubMed ID: 30021323
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug Repositioning for Alzheimer's Disease: Finding Hidden Clues in Old Drugs.
    Ihara M; Saito S
    J Alzheimers Dis; 2020; 74(4):1013-1028. PubMed ID: 32144994
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Do Cancer Drugs Counteract Neurodegeneration? Repurposing for Alzheimer's Disease.
    Monacelli F; Cea M; Borghi R; Odetti P; Nencioni A
    J Alzheimers Dis; 2017; 55(4):1295-1306. PubMed ID: 27834781
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epigenetic Drug Repositioning for Alzheimer's Disease Based on Epigenetic Targets in Human Interactome.
    Chatterjee P; Roy D; Rathi N
    J Alzheimers Dis; 2018; 61(1):53-65. PubMed ID: 29199645
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In silico repurposing of antipsychotic drugs for Alzheimer's disease.
    Kumar S; Chowdhury S; Kumar S
    BMC Neurosci; 2017 Oct; 18(1):76. PubMed ID: 29078760
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Repositioning and development of new treatments for neurodegenerative diseases: Focus on neuroinflammation.
    Arbo BD; Schimith LE; Goulart Dos Santos M; Hort MA
    Eur J Pharmacol; 2022 Mar; 919():174800. PubMed ID: 35131314
    [TBL] [Abstract][Full Text] [Related]  

  • 35. On the edge: pharmacological evidence for anxiety-related behavior in zebrafish larvae.
    Richendrfer H; Pelkowski SD; Colwill RM; Creton R
    Behav Brain Res; 2012 Mar; 228(1):99-106. PubMed ID: 22155488
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasmalogens improve swimming performance by modulating the expression of genes involved in amino acid and lipid metabolism, oxidative stress, and ferroptosis in an Alzheimer's disease zebrafish model.
    Feng J; Song G; Wu Y; Chen X; Pang J; Xu Y; Shen Q; Guo S; Zhang M
    Food Funct; 2021 Nov; 12(23):12087-12097. PubMed ID: 34783821
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Brilliance of the Zebrafish Model: Perception on Behavior and Alzheimer's Disease.
    Shenoy A; Banerjee M; Upadhya A; Bagwe-Parab S; Kaur G
    Front Behav Neurosci; 2022; 16():861155. PubMed ID: 35769627
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of Zebrafish Genetic Models to Study Etiology of the Amyloid-Beta and Neurofibrillary Tangle Pathways in Alzheimer's Disease.
    Kiper K; Freeman JL
    Curr Neuropharmacol; 2022 Mar; 20(3):524-539. PubMed ID: 34030617
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Old Drugs with New Tricks: Paradigm in Drug Development Pipeline for Alzheimer's Disease.
    Dalvi T; Dewangan B; Das R; Rani J; Shinde SD; Vhora N; Jain A; Sahu B
    Cent Nerv Syst Agents Med Chem; 2020; 20(3):157-176. PubMed ID: 33087034
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hybrid neural network approaches to predict drug-target binding affinity for drug repurposing: screening for potential leads for Alzheimer's disease.
    Wu X; Li Z; Chen G; Yin Y; Chen CY
    Front Mol Biosci; 2023; 10():1227371. PubMed ID: 37441162
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.